Till­man Gern­gross leads a pack of biotech CEOs out the door; With eyes on pipeline ex­pan­sion, Po­sei­da woos a gene ther­a­py ex­ec from No­var­tis

As mar­ket volatil­i­ty sweeps through the land­scape, CEO changes are re­al­ly ramp­ing up, and top­ping the list is Till­man Gern­gross, a force in the an­ti­body space who hitched his wag­on to find­ing an­oth­er Covid-19 so­lu­tion by co-found­ing Ada­gio Ther­a­peu­tics. With big in­vestors back­ing him, the big dreams sput­tered when ADG20 proved less ef­fec­tive against Omi­cron in De­cem­ber. Gern­gross has now re­signed as CEO, hand­ing things over to COO David Her­ing on an in­ter­im ba­sis un­til a per­ma­nent suc­ces­sor is named. No stranger to the Covid vac­cine fight, Her­ing was poached from his role as glob­al mR­NA busi­ness lead of Pfiz­er in Ju­ly 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER